ASCO 2026
I can’t believe it will be my 11th year in attendance at ASCO. While it wouldn’t take much to sell me to go to Chicago in June when the weather is quite beautiful and the Magnificent Mile looks magnificent… the conference alone has much to offer.
A few things of specific interest to me this year are:
Revolution Medicine’s daraxonrasib… finally something in PDAC to make us sit up and take attention! A terrible cancer to with an incredible fortress and one that has had little to nothing but chemotherapy options.
Plenary Session (Hall B1): Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. May 31st 1:00 - 4:00 PM Hall B1
Akeso /Summit Therapeutic’s ivonescimab (AK112) which is a first-in-class PD-1 × VEGF bispecific antibody. It is designed to combine checkpoint inhibition with anti-angiogenic activity in one molecule.
Plenary Session (Hall B1): Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
Avenzo Therapeutics, out of San Diego, Avenzo will present updated safety and efficacy results from the Phase 1 portion of its ongoing Phase 1/2 clinical study of AVZO-021, its potential best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor.
Poster Session: Breast Cancer—Metastatic Jun 1st 1:30 - 4:30 PM Hall A -A phase 1/2, first-in-human study of AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), as monotherapy and in combination for patients with advanced solid tumors, including hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC) and cyclin E1 (CCNE1)–amplified solid tumors
Zentalis, another new company I have never heard of out of San Diego, is one of the first to have a product in trial for a first-in-class WEE1 inhibitor - azenosertib. To be used as a monotherapy for Cyclin E1-positive platinum-resistant ovarian cancer. They selected 400mg once daily on a 5-days-on, 2-days-off schedule (400mg QD 5:2) as the pivotal study dose. DENALI Part 2 topline readout expected towards the end of 2026 to support potential accelerated approval; ASPENOVA Phase 3 trial first patient dosed this month designed to support full approval.
Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology on May 30th 1:30 - 4:30 PM, Hall A. It will featuring results from Part 1 of the Phase 1b MUIR trial, focusing on an evaluation of azenosertib in combination with paclitaxel in platinum-resistant ovarian cancer (PROC). The data will showcase combinability and activity in an all-comer setting, demonstrating the broad potential for azenosertib in multiple lines of ovarian cancer and other tumor types.